List of Tekturna drug patents
Tekturna is owned by Noden Pharma.
Tekturna contains Aliskiren Hemifumarate.
Tekturna has a total of 2 drug patents out of which 0 drug patents have expired.
Tekturna was authorised for market use on 05 March, 2007.
Tekturna is available in tablet;oral dosage forms.
The generics of Tekturna are possible to be released after 19 August, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617595 | NODEN PHARMA | Galenic formulations of organic compounds |
Feb, 2026
(3 years from now) | |
|
US8617595
(Pediatric) | NODEN PHARMA | Galenic formulations of organic compounds |
Aug, 2026
(3 years from now) | |
Drugs and Companies using ALISKIREN HEMIFUMARATE ingredient
Market Authorisation Date: 05 March, 2007
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of TEKTURNA before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic